This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
In patients with multiple sclerosis (MS), activation of immune cells and breakdown of the blood–brain barrier (BBB) lead to demyelination and axon injury. Although repairing damage to neurons is not possible, immunomodulating therapies can reduce the inflammatory processes that lead to demyelination. Interferon-beta (IFN-β) is a polypeptide, normally produced by fibroblasts, that has antiviral and antiproliferative effects. Binding of IFN-β to its receptor induces a complex transcriptional response. In immune cells (the most likely target of IFN-β’s therapeutic effect in MS), IFN-β reduces antigen presentation and T-cell proliferation, alters cytokine and matrix metalloproteinase (MMP) expression, and restores suppressor function. Therapeutic forms of IFN-β can be produced in bacterial expression systems (IFN-β1b) or in mammalian cells (IFN-β1a). These forms have some differences in their amino acid sequence and posttranslational modifications, but the transcriptional response to IFN- β1b and IFN-β1a appears to be similar, if not indistinguishable. However, the biological response and the clinical effect do vary with changes in the dosing frequency of IFN-β. In clinical trials, IFN-β1a IM administered weekly elicits a transient biological response compared to IFN-β1b administered SC every other day or IFN-β1a (administered SC three times per week). Comparative clinical trials suggest that the differences in the biological response are clinically meaningful: more frequent IFN-β administration produces superior clinical responses.
Footnotes
-
Disclosure: Dr. Markowitz receives research funding and/or honoraria from Berlex, Inc., Biogen Idec, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., PDL BioPharma, Inc., Pfizer, Inc., Serono, Inc., Teva, and Wyeth Pharmaceuticals. Publication of this supplement was supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology®.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
